Today NIH announced awards to six companies for a total of $98.35 million to support scale-up and manufacturing for a new set of COVID-19 testing technologies, funded by the Rapid Acceleration of Diagnostics (RADx) initiative and the Biomedical Advanced Research and Development Authority (BARDA). The new technologies include point-of-care tests and a mobile-lab testing system that use innovative approaches to allow for new modes of collection, processing, and return of results. These contracts add to awards made to seven companies in July and nine in September. The RADx initiative continues to support the development of a diverse group of tests to meet the needs of different communities.
Please visit the NIBIB page to learn more about NIH’s efforts to meet the U.S. demand for COVID-19 testing.
No hay comentarios:
Publicar un comentario